A recent, frequently quoted study has suggested that for bloodstream infections (BSIs) due to
extended-spectrum β-lactamase–producing Enterobacteriaceae (ESBL) Escherichia coli …

Background There is little information about the efficacy of active alternative drugs to
carbapenems except β-lactam/β-lactamase inhibitors for the treatment of bloodstream …

Background Infections due to extended-spectrum beta-lactamase (ESBL)-producing
Enterobacteriaceae pose a major public health threat due to poor outcomes and high …

Background Carbapenems are widely used for the management of bloodstream infections
(BSIs) caused by extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL …

The spread of extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae
(ESBL-E) is leading to increased carbapenem consumption. Alternatives to carbapenems …

Objectives Carbapenems are first-line agents for severe infections with extended-spectrum
beta-lactamase (ESBL)-producing bacteria. The use of carbapenems, however, is …

Backgroung: Bloodstream infection (BSI) due to extended-spectrum β-lactamase (ESBL)
producing Enterobacteriaceae are a major cause of in-hospital mortality. The effect on …

Bloodstream infections (BSI) caused by extended-spectrum β-lactamase (ESBL)-producing
organisms markedly increase the rates of treatment failure and death. We conducted a …

Background Extended-spectrum β-lactamase (ESBL) producing Enterobacteriaceae are
often susceptible in vitro to β-lactam/β-lactamase inhibitor (BLBLI) combination antibiotics …

Objective Risk factors and outcomes associated with extended-spectrum beta-lactamase
(ESBL)-producing Escherichia coli (E. coli) bloodstream infections (BSI) are not yet fully …